CD8A and neoplasm: B16 tumour-bearing C57BL/6J mice subjected to DR were administered either anti-PD1 or control IgG antibodies 7 days post tumour implantation, and CD8+ TIL phenotypes were analysed after 15 days of treatment (as in Extended Data Fig. 10d).